Gujarat Kidney IPO Performance Analyzed

Gujarat Kidney and Super Speciality, a healthcare company, started trading on December 30, 2025, after its initial public offering (IPO). The stock’s performance was very strong, opening higher than expected. This indicates positive investor confidence in the company’s future.

Key Points

• Strong debut: Shares listed at ₹120, a 5.3% premium.
• BSE listing: Opened at ₹120.75, a 6% premium.
• Above Grey Market Estimates: GMP of 1.32% indicated strong demand.
• High Subscription Rate: 5.21x subscription shows investor interest.
• Retail Investors Driven: Oversubscription of 19.04x demonstrates retail appeal.
• Funds Allocation: Proceeds used for hospitals, equipment, and expansion.

IPO Details

Gujarat Kidney raised ₹250.80 crore by selling 22 million shares between December 22nd and 24th, 2025. The price range was set from ₹108 to ₹114 per share. Investors showed significant interest, with a subscription rate of 5.21 times.

Grey Market Activity

Before the IPO, the company’s unlisted shares were trading at around ₹115.50 per share, suggesting a grey market premium (GMP) of ₹1.50, or 1.32% over the issue price. This reflected optimistic expectations about the company’s potential.

Use of Funds

The company planned to use the money raised to buy a hospital, purchase medical equipment, and build new facilities. Specifically, the funds will be used for acquiring Parekhs Hospital, part-payment for Ashwini Medical Centre, additional shares in Harmony Medicare, building a hospital in Vadodara, robotics equipment, and repaying debts.

Registrars and Managers

MUFG Intime was the registrar for the IPO. Nirbhay Capital Services acted as the sole book-running lead manager. These firms play a crucial role in the IPO process.

Investing in promising healthcare companies can yield significant returns for investors.